Benedetta Pellegrino

Parma, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications

CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC.

CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC.

Journal: Cancer research communications
Published: August 04, 2025

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.

Journal: NPJ breast cancer
Published: July 31, 2025

Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma.

Assessing Determinants of Response to PARP Inhibition in Germline ATM Mutant Melanoma.

Journal: International journal of molecular sciences
Published: July 02, 2025

Comprehensive analysis of BRCA1/2 mutations, "BRCAness" and PARP inhibitors in melanoma.

Comprehensive analysis of BRCA1/2 mutations, "BRCAness" and PARP inhibitors in melanoma.

Journal: Critical reviews in oncology/hematology
Published: June 23, 2025

SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy.

SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy.

Journal: Cancers
Published: March 13, 2025

Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC).

Journal: Tumori
Published: December 16, 2024

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

Journal: Cancer research
Published: July 23, 2024

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.

Unraveling the complexity of HRD assessment in ovarian cancer by combining genomic and functional approaches: translational analyses of MITO16-MaNGO-OV-2 trial.

Journal: ESMO open
Published: July 03, 2024

Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making.

Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making.

Journal: Tumori
Published: June 13, 2024

The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.

The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study.

Journal: Breast cancer research and treatment
Published: March 10, 2024

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies.

Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies.

Journal: Journal of clinical medicine
Published: February 20, 2024

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents.

Journal: ESMO open
Published: February 12, 2024
Showing 1-12 of 49

Last Updated: 09/26/2026